Three-Week Radiation Therapy Treatment Given Post Mastectomy Is Safe and Effective
Rutgers Cancer Institute of New Jersey research shows low toxicity in shorter treatment course
Article ID: 673908
Released: 1-May-2017 4:05 PM EDT
Source Newsroom: Rutgers Cancer Institute of New Jersey
Newswise — New Brunswick, N.J., May 1, 2017 – A shorter course of radiation therapy given to breast cancer patients following mastectomy is safe and effective and cuts treatment time in half. That is according to data from a phase II clinical trial conducted by Rutgers Cancer Institute of New Jersey investigators and other colleagues who examined a hypofractionated regimen given over three weeks versus the traditional six week course of treatment. The work appears in the current online edition of the Journal of Clinical Oncology (http://ascopubs.org/doi/full/10.1200/JCO.2016.70.7158).
When there is a concern that cancer cells may remain in the chest wall and lymph node regions following a mastectomy, a patient may be given targeted radiation over a five to six week period to further treat the breast cancer. “Receiving radiation for that long of a period becomes a quality of life issue for many patients. This includes the inconvenience of frequent travel to the treatment facility, as well as fatigue and other common side effects that can cause lost time at work and other challenges,” notes the work’s senior investigator Bruce G. Haffty, MD, professor and chair, Department of Radiation Oncology at Rutgers Cancer Institute, Rutgers Robert Wood Johnson Medical School and Rutgers New Jersey Medical School.
Researchers explored an accelerated course of radiation that cut treatment time in half. Currently, there is limited data supporting this type of treatment in this patient population.
From 2010 to 2014, 67 eligible patients with stage II to IIIa breast cancer were enrolled at Rutgers Cancer Institute of New Jersey and Huntsman Cancer Institute at the University of Utah. A dose of 36.63 Gy (a unit of radiation measurement) was given in 11 fractions of 3.33 Gy each. The fractions were delivered over a three-week period to the chest wall and area lymph nodes. The treatment also allowed for an optional four fractions (3.33 Gy each) of radiation to the chest wall at the mastectomy scar area, resulting in a total of 15 treatments over three weeks.
The aim was to not have any reported treatment toxicities of grade three or above. After a median follow up of 32 months, no grade three toxicities or higher were reported. There were 29 grade two toxicities reported, with a majority being skin rash followed by fatigue, similar to what may be experienced with the longer five to six week course of treatment. The estimated three-year survival rate of the cancer not coming back to the breast area was 89.2 percent. The estimated three-year survival rate for the cancer not coming back and spreading beyond the breast was 90.3 percent.
“While shorter courses of radiation therapy have been adopted in patients receiving radiation therapy to the breast alone after lumpectomy, there has not been adoption of shorter courses of treatment to the chest wall and lymph nodes after mastectomy. This trial demonstrated the safety of this shorter course approach in a prospective phase II study,” notes Dr. Haffty.
Based on this study, a larger post-mastectomy randomized trial has been developed through the Alliance Cooperative Group with Haffty and current study investigators Matt Poppe of the Huntsman Cancer Institute and Atif J. Khan of Memorial Sloan Kettering Cancer Center leading the effort. In this phase III trial, a shorter course of radiation in the post-mastectomy, post-reconstruction setting will be compared to the more conventional five to six week course of treatment.
Along with Haffty, Poppe and Khan, other investigators on the current study include Sharad Goyal, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School; Kristine E. Kokeny, Huntsman Cancer Institute, Thomas Kearney, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School; Laurie Kirstein, Memorial Sloan Kettering Cancer Center; Deborah Toppmeyer, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School; Dirk F. Moore and Chunxia Chen, both Rutgers Cancer Institute and Rutgers School of Public Health; and David K. Gaffney, Huntsman Cancer Institute.
This work was supported in part by the National Institutes of Health Cancer Center Support Grant (P30CA072720) and the Breast Cancer Research Foundation (Haffty).
About Rutgers Cancer Institute of New Jersey
Rutgers Cancer Institute of New Jersey (www.cinj.org) is the state’s first and only National Cancer Institute-designated Comprehensive Cancer Center. As part of Rutgers, The State University of New Jersey, Rutgers Cancer Institute is dedicated to improving the detection, treatment and care of patients with cancer, and to serving as an education resource for cancer prevention both at its flagship New Brunswick location and at its Newark campus at Rutgers Cancer Institute of New Jersey at University Hospital. Physician-scientists across Rutgers Cancer Institute also engage in translational research, transforming their laboratory discoveries into clinical practice that supports patients on both campuses. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit www.cinj.org/giving. Follow us on Facebook at www.facebook.com/TheCINJ.